[{"id":"677f2d62-1a83-48ae-896f-c6ea6bc8dbd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05504213","created_at":"2022-08-17T13:55:01.025Z","updated_at":"2024-07-02T16:36:05.306Z","phase":"Phase 1","brief_title":"A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT05504213","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • HS-10352"],"overall_status":"Recruiting","enrollment":" Enrollment 224","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-08-17"},{"id":"77f421a5-456a-4c4b-9e27-6d5296da3aeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04631835","created_at":"2021-01-19T20:36:39.421Z","updated_at":"2024-07-02T16:36:08.713Z","phase":"Phase 1","brief_title":"Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT04631835","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS-10352"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2022-06-15"}]